Endo International PLC said Monday that it has agreed to sell its men’s health and prostate businesses to Boston Scientific for $1.6 billion, in a bid to streamline and focus instead on its core pharmaceuticals business.
from WSJ.com: US Business http://ift.tt/1BxLpzQ
via IFTTT
from WSJ.com: US Business http://ift.tt/1BxLpzQ
via IFTTT
No comments:
Post a Comment